Satellos Bioscience Inc.
MSLEHealthcare|Biotechnology|CA
$7.19
+0.84 (+13.23%)
DCF Value
$4.97
Tangible Book / Share
$2.87
Cash / Share
$2.96
About
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Stock Price
+1.6%(1Y)
1M
-2.2%
3M
-28.3%
6M
-6.5%
YTD
+1.6%
1Y
+1.6%
3Y
+1.6%
5Y
+1.6%
Pipeline Summary
4 total trials0
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
Not Yet Recruiting: 1Active: 1By Invitation: 1Completed: 1
Active Trials (1)
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
NCT07287189Duchenne Muscular Dystrophy
Phase 2Active
Enrollment: 51 participants
Key Facts
Market Cap$9.3M
Employees18
CEOFrancis Gleeson
IPO DateAug 3, 2012
Beta1.17
52-Week Range$5.304 – $13.395
Avg Volume57,434
ExchangeNASDAQ
Websitesatellos.com
Ownership
Float82.6%
Shares Outstanding1.3M
Recent News
Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Rated “Moderate Buy” by Wall Street Brokerages
Sep 28, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:23 AM